Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.

Novo Nordisk reported results Monday for its trial to determine whether the active ingredient in Ozempic and Wegovy could slow the progression of Alzheimer's. Sergei Gapon / AFP / Getty Images Close Key Takeaways Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial. The company had been looking to determine whether semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, could also slow the cognitive decline associated wit ...